

Highly Specialised Technology Evaluation Committee Interests Register
Topic: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]
Publication Date: 11/09/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Emtiyaz Chowdhury	Committee member	Non-Financial Professional interests	Emtiyaz employer is Parexel. Parexel provides services to Vertex. But he has not been involved with any activities related to this technology in either indication.	23.01.2024	It was agreed his declarations would not prevent Emtiyaz from participating in discussions for this appraisal.
Stuart Mealing	Committee member	Non-Financial Professional interests	Stuart noted that other members of YHEC have undertaken work for Vertex but not in these therapy areas and he has never personally worked for Vertex.	23.01.2024	It was agreed his declarations would not prevent Stuart from participating in discussions for this appraisal.
Emma Drasar	Clinical expert	Direct financial & non-financial interests	Emma has provided paid consultancy and speaking services for Pfizer, Vertex, Novartis and UKTS	15.05.2023	It was agreed her declarations would not prevent Emma from providing expert advice to committee.
Ben Carpenter	Clinical expert	Direct financial & non-financial interest and indirect interests	Ben was a Vertex meeting speaker in July 2023. And took part in a Vertex Ad board in Dec 2021. He is involved in ongoing CRISPR studies	16.05.2023	It was agreed his declarations would not prevent Ben from providing expert advice to committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			and Potential unit (UCLH) delivering such therapies		